A phase II clinical trial for HNSCC (NCT04632992) is currently underway, focusing on evaluating its early anti-tumor activity and safety in HNSCC with abnormal activation of the PI3K/Akt/mTOR pathway [17]. This evidence concerns the gene MTOR and neoplasm.